880144-50-3

Upstream product

• 880144-49-0 tert-butyl [(6S,9R)-6-(2,3-difluorophenyl)-3-(1-methoxy-1-methylethyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-9-yl]carbamate 
• 870-63-3 prenyl bromide 
• 115270-03-6 1--3-methyl-2-butene 
• 885032-74-6 tert-butyl (6S,9R)-6-(2,3-difluorophenyl)-3-(1-hydroxy-1-methylethyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-9-ylcarbamate 
• 880144-46-7 tert-butyl (3R,6S)-6-(2,3-difluorophenyl)-2-thioxoazepan-3-ylcarbamate 
• 885033-77-2 1-amino-3-hydroxy-3-methylbutan-2-one hydrochloride 
• 885032-39-3 di-tert-butyl (3-hydroxy-3-methyl-2-oxobutyl)imidodicarbonate 
• 1236226-80-4 1-amino-3-methyl-2,3-butanediol 
• 781650-32-6 tert-butyl [(3R,6S)-6-(2,3-difluorophenyl)-2-oxoazepan-3-yl]carbamate 

Downstream Products

• 885030-22-8 C₂₉H₃₂F₂N₆O₄ 

Relevant academic research and scientific papers

Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918

In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacemen

CARBOXAMIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: I wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as mi